NCT06217094 2026-02-18
Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
University of Florida
Phase 1 Withdrawn
Clinical Trials
96 trialsNCT06994299 2025-11-18
PRISM
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT06361758 2025-05-23
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Shanghai Zhongshan Hospital
Phase 2 Withdrawn
NCT02939807 2025-04-27
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
Medical University of South Carolina
Phase 2 Withdrawn
NCT03636607 2025-03-24
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase NA Withdrawn
NCT04976660 2025-03-18
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
Portage Biotech
Phase 1/2 Withdrawn
NCT05418387 2024-11-25
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
University of Arizona
Phase NA Withdrawn
NCT00756782 2024-09-04
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
Taiho Oncology, Inc.
Phase 2 Withdrawn
NCT05211388 2024-08-29
Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors
University of Cincinnati
Phase NA Withdrawn
NCT06337162 2024-08-09
HCC
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT05641922 2023-11-27
PANORAMA2
Techsomed Medical Technologies LTD
Phase NA Withdrawn
NCT03722498 2023-07-11
Phase â…¡ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Sun Yat-sen University
Phase 2 Withdrawn
NCT05886257 2023-06-02
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
Sun Yat-sen University
Phase 2 Withdrawn
NCT05039736 2023-05-12
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02174575 2023-05-03
Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
Tokyo Medical and Dental University
Phase 4 Withdrawn
NCT05157451 2023-03-23
Y-90 Versus SBRT for Inoperable HCC
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT05628545 2023-01-18
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Guangdong GD Kongming Biotech LLC
Phase 1/2 Withdrawn
NCT04178642 2022-12-14
LIDA-ADJ
University Hospital, Montpellier
Phase 2 Withdrawn
NCT05327738 2022-12-14
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT03634683 2022-06-30
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation
Lion TCR Pte. Ltd.
Phase 1/2 Withdrawn
NCT04465734 2022-05-05
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT04231929 2022-03-28
BIOPEARL-FIRST
Terumo Europe N.V.
Phase NA Withdrawn
NCT03908255 2022-01-28
BCAA in HCC
Louisiana State University Health Sciences Center in New Orleans
Phase 2 Withdrawn
NCT04947371 2021-07-01
Adjuvant Therapy With Anlotinib for HCC
Shanghai Zhongshan Hospital
Phase 2 Withdrawn
NCT03452553 2021-04-21
Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMIâ„¢) Loaded With Doxorubicin
Boston Scientific Corporation
Phase NA Withdrawn
NCT04404647 2021-03-26
Irreversible Electroporation of Unresectable Liver Tumors
Aalborg University Hospital
Phase NA Withdrawn
NCT04526080 2021-02-26
TheraBionics
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT02129322 2021-02-15
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
Zhejiang University
Phase 2 Withdrawn
NCT03040453 2020-11-30
IRAL
Karolinska Institutet
Phase NA Withdrawn
NCT03063840 2020-11-20
Microwave Ablation for the Treatment of Malignant Liver Tumors Closed to Intrahepatic Vessels
National Taiwan University Hospital
Phase NA Withdrawn
NCT04270461 2020-10-22
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
Jiujiang University Affiliated Hospital
Phase 1 Withdrawn
NCT04044326 2020-09-14
The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors
National Taiwan University Hospital
Phase NA Withdrawn
NCT04546802 2020-09-14
HATCHeT
Bayside Health
Phase 3 Withdrawn
NCT02723942 2020-07-16
CAR-T Cell Immunotherapy for HCC Targeting GPC3
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT04395118 2020-07-02
STOP-HCC
University of Texas Southwestern Medical Center
Phase NA Withdrawn
NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT04093648 2020-05-20
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
Baylor College of Medicine
Phase 1 Withdrawn
NCT04025567 2020-03-16
Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT04158700 2020-02-19
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1/2 Withdrawn
NCT02580253 2020-02-17
Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation
Zhejiang University
Phase 2 Withdrawn
NCT03217253 2020-02-07
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT01923233 2020-01-22
In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer
Mirror Biologics, Inc.
Phase 1/2 Withdrawn
NCT01995227 2020-01-22
An Individualized Anti-Cancer Vaccine Study in Patients With HCC
Mirror Biologics, Inc.
Phase 1/2 Withdrawn
NCT02289300 2020-01-13
A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
A2 Healthcare Taiwan Corporation
Phase 2 Withdrawn
NCT04044651 2020-01-09
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Sun Yat-sen University
Phase 2/3 Withdrawn
NCT03738111 2019-09-25
Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
Lee's Pharmaceutical Limited
Phase 1 Withdrawn
NCT02527772 2019-06-04
LD-FOX4/HCC
Guangxi Medical University
Phase 2/3 Withdrawn
NCT02534337 2019-06-04
Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Guangxi Medical University
Phase 2/3 Withdrawn
NCT02584556 2019-06-04
Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma
Guangxi Medical University
Phase 2/3 Withdrawn
NCT02585479 2019-06-04
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
Guangxi Medical University
Phase 2/3 Withdrawn